Fresenius SE & Co KGAA O.N. (FREG)

Currency in EUR
43.000
+1.270(+3.04%)
Closed·
Earnings results expected in 15 days
FREG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
41.88043.160
52 wk Range
35.11052.960
Key Statistics
Prev. Close
43
Open
41.88
Day's Range
41.88-43.16
52 wk Range
35.11-52.96
Volume
1.27M
Average Volume (3m)
1.3M
1-Year Change
5.1602%
Book Value / Share
35.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FREG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
54.221
Upside
+26.10%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 54.221
(+26.10% Upside)

Earnings

Latest Release
06-05-2026
EPS / Forecast
0.82 / 0.89
Revenue / Forecast
5.74B / 5.83B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.69%
Dividend Yield
2.52%
Industry Median 2.23%
Annualised payout
1.05
Paid annually
5-Years Growth
+3.60%
Growth Streak

FREG Income Statement

Compare FREG to Peers and Sector

Metrics to compare
FREG
Peers
Sector
Relationship
P/E Ratio
16.0x18.5x−0.4x
PEG Ratio
0.060.250.00
Price/Book
1.2x1.8x2.6x
Price / LTM Sales
1.1x1.9x3.0x
Upside (Analyst Target)
30.6%20.0%53.2%
Fair Value Upside
Unlock27.4%9.0%Unlock

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Employees
177783
Market
Germany

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
191.49M34.00%7.99B
Other Institutional Investors
175.97M31.24%7.34B
Public Companies & Retail Investors
195.78M34.76%8.17B
Total
563.24M100.00%23.5B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Else Kröner Fresenius Foundation27.11%15,26,79,50963,71,316
BlackRock, Inc.5.06%2,85,18,43911,90,074

FAQ

What Is the Fresenius SE (FREG) Share Price Today?

The Fresenius SE share price today is 43.000.

What is the current Fresenius SE (FREG) share price and day range?

As of 21-07-2026, the Fresenius SE share price is 43.000, with a previous close of 43.000. The share price has ranged from 41.880 to 43.160 today, while the 52-week range spans from 35.110 to 52.960.

What Is the Fresenius SE Market Cap?

As of today, Fresenius SE market cap is 24.250B.

Does Fresenius SE Pay Dividends? What's The Current Dividend Yield?

The Fresenius SE dividend yield is 2.44%.

What Is the Fresenius SE (FREG) Share Price Target?

The average 12-month share price target for Fresenius SE is 54.221, with a high estimate of 59 and a low estimate of 48. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +26.10% Upside potential.

What Is Fresenius SE's Earnings Per Share (TTM)?

The Fresenius SE EPS (TTM) is 2.688.

When Is the Next Fresenius SE Earnings Date?

Fresenius SE will release its next earnings report on 05-08-2026.

From a Technical Analysis Perspective, Is FREG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Fresenius SE Trade On?

Fresenius SE is listed and trades on the Frankfurt Stock Exchange.

What Is the Stock Symbol for Fresenius SE?

The stock symbol for Fresenius SE is "FREG."

How Many Times Has Fresenius SE Stock Split?

Fresenius SE has split 4 times.

How Many Employees Does Fresenius SE Have?

Fresenius SE has 177783 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.